{
    "info": {
        "nct_id": "NCT04827745",
        "official_title": "A Multicenter Phase II Study of Blinatumomab for Treatment of Adult Patients With Morphologic Relapsed/Refractory or Measurable Residual Disease (MRD) CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)",
        "inclusion_criteria": "* Subjects must have histologically or cytologically confirmed R/R CD19-positive MPAL based on the WHO criteria, OR CD19-positive MPAL in CR/CRh/CRi/CRp after at least one chemotherapy block of standard ALL or AML therapy with detectable MRD ≥ 0.1%. Primary refractory MPAL is defined by absence of CR/CRh/CRi/CRp after at least one cycle of standard AML/ALL induction therapy. A patient has relapsed MPAL if they achieved a CR/CRh/CRi/CRp after induction therapy (CR1) and has then relapsed during, or after continuation of therapy.\n* Age 18 years and older\n* Subjects who have undergone allo-HSCT are eligible if they are ≥ 4 weeks post stem cell infusion, have no evidence of GVHD > Grade 2, and are at least ≥ 1 week off all immunosuppressive therapy\n* Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed at least 2 weeks prior to day 1 of treatment on the study. Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry.\n* ECOG performance status < 3\n* Subjects must have organ function as below:\n\n  * Direct bilirubin ≤ 2.5 mg/dL\n  * AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal\n  * Serum creatinine ≤ 3 mg/dL\n* Subjects with a history of CNS leukemia must be clinically stable with a flow cytometric clear CSF in the 2 weeks prior to day 1 of blinatumomab administration. Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration. Subject can receive subsequent prophylactic intrathecal chemotherapy.\n* Female subjects of childbearing potential must have a negative pregnancy test\n* Ability to understand and willingness to sign a written informed consent document\n* Agree to comply with the study requirements and agree to come to the clinic/hospital for required study visits\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Subjects receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy not including corticosteroids or hydroxyurea\n* Subjects with acute leukemia with any of the following cytogenetic abnormalities:\n\n  t(15;17)(q24;q21) PML/RARA, t(8;21)(q22;q22) RUNX1/RUNX1T1, inv(16)(p13q22)/t(16;16)(p13;q22) CBFB-MYH11\n* A history or presence of clinically relevant CNS pathology (e.g., as epilepsy, paresis, aphasia, stroke, severe brain injuries, dementia, cerebellar disease, psychosis)\n* Hyperleukocytosis with > 50,000 blasts/µL. Hydroxyurea for blast count control is permitted before starting treatment and up to maximum of 10 days after starting treatment on the study. The WBC need not reach 50,000/µL to start hydroxyurea during protocol; the decision to start hydroxyurea during this time is at the discretion of the treating physician\n* Active, uncontrolled infection; subjects with infection under active treatment and controlled with antimicrobials are eligible\n* Pregnant women\n* Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Serum creatinine ≤ 3 mg/dL",
                "criterions": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 3 mg/dL",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Serum creatinine ≤ 3 mg/dL",
                        "criterion": "serum creatinine",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* ECOG performance status < 3",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status < 3",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status < 3",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Age 18 years and older",
                "criterions": [
                    {
                        "exact_snippets": "Age 18 years and older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age 18 years and older",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Ability to understand and willingness to sign a written informed consent document",
                "criterions": [
                    {
                        "exact_snippets": "Ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects must have organ function as below:",
                "criterions": [
                    {
                        "exact_snippets": "Subjects must have organ function as below",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "function",
                            "expected_value": "as specified below"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subjects must have organ function as below",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "function",
                            "expected_value": "as specified below"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Agree to comply with the study requirements and agree to come to the clinic/hospital for required study visits",
                "criterions": [
                    {
                        "exact_snippets": "Agree to comply with the study requirements",
                        "criterion": "willingness to comply with study requirements",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to come to the clinic/hospital for required study visits",
                        "criterion": "willingness to attend study visits",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agree to comply with the study requirements",
                        "criterion": "willingness to comply with study requirements",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "agree to come to the clinic/hospital for required study visits",
                        "criterion": "willingness to attend study visits",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Direct bilirubin ≤ 2.5 mg/dL",
                "criterions": [
                    {
                        "exact_snippets": "Direct bilirubin ≤ 2.5 mg/dL",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Direct bilirubin ≤ 2.5 mg/dL",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "mg/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed at least 2 weeks prior to day 1 of treatment on the study. Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry.",
                "criterions": [
                    {
                        "exact_snippets": "Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed at least 2 weeks prior to day 1 of treatment on the study.",
                        "criterion": "previous cytotoxic chemotherapy (except for hydroxyurea)",
                        "requirement": {
                            "requirement_type": "completion interval before study treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry.",
                        "criterion": "hematologic abnormalities at study entry",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed at least 2 weeks prior to day 1 of treatment on the study.",
                                "criterion": "previous cytotoxic chemotherapy (except for hydroxyurea)",
                                "requirement": {
                                    "requirement_type": "completion interval before study treatment",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry.",
                                "criterion": "hematologic abnormalities at study entry",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Female subjects of childbearing potential must have a negative pregnancy test",
                "criterions": [
                    {
                        "exact_snippets": "Female subjects of childbearing potential",
                        "criterion": "sex and childbearing potential",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Female subjects of childbearing potential",
                        "criterion": "sex and childbearing potential",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have a negative pregnancy test",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Female subjects of childbearing potential",
                                "criterion": "sex and childbearing potential",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "exact_snippets": "Female subjects of childbearing potential",
                                "criterion": "sex and childbearing potential",
                                "requirement": {
                                    "requirement_type": "childbearing potential",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "must have a negative pregnancy test",
                        "criterion": "pregnancy test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                "criterions": [
                    {
                        "exact_snippets": "AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "X institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "X institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                        "criterion": "alkaline phosphatase level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "X institutional upper limit of normal"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                        "criterion": "AST level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "X institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                        "criterion": "ALT level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "X institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal",
                        "criterion": "alkaline phosphatase level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "X institutional upper limit of normal"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Active, uncontrolled infection; subjects with infection under active treatment and controlled with antimicrobials are eligible",
                "criterions": [
                    {
                        "exact_snippets": "Active, uncontrolled infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Active, uncontrolled infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "subjects with infection under active treatment and controlled with antimicrobials are eligible",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "treatment_status",
                            "expected_value": "under active treatment"
                        }
                    },
                    {
                        "exact_snippets": "subjects with infection under active treatment and controlled with antimicrobials are eligible",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "subjects with infection under active treatment and controlled with antimicrobials are eligible",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "treatment_type",
                            "expected_value": "antimicrobials"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active, uncontrolled infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Active, uncontrolled infection",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "subjects with infection under active treatment and controlled with antimicrobials are eligible",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "treatment_status",
                                    "expected_value": "under active treatment"
                                }
                            },
                            {
                                "exact_snippets": "subjects with infection under active treatment and controlled with antimicrobials are eligible",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "control_status",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "subjects with infection under active treatment and controlled with antimicrobials are eligible",
                                "criterion": "infection",
                                "requirement": {
                                    "requirement_type": "treatment_type",
                                    "expected_value": "antimicrobials"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant women",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Pregnant women",
                    "criterion": "pregnancy status",
                    "requirement": {
                        "requirement_type": "pregnancy",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Hyperleukocytosis with > 50,000 blasts/µL. Hydroxyurea for blast count control is permitted before starting treatment and up to maximum of 10 days after starting treatment on the study. The WBC need not reach 50,000/µL to start hydroxyurea during protocol; the decision to start hydroxyurea during this time is at the discretion of the treating physician",
                "criterions": [
                    {
                        "exact_snippets": "Hyperleukocytosis with > 50,000 blasts/µL",
                        "criterion": "blast count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50000,
                                "unit": "blasts/µL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hyperleukocytosis with > 50,000 blasts/µL",
                        "criterion": "blast count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50000,
                                "unit": "blasts/µL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with acute leukemia with any of the following cytogenetic abnormalities:",
                "criterions": [
                    {
                        "exact_snippets": "Subjects with acute leukemia",
                        "criterion": "acute leukemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any of the following cytogenetic abnormalities",
                        "criterion": "cytogenetic abnormalities",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Subjects with acute leukemia",
                                "criterion": "acute leukemia",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "any of the following cytogenetic abnormalities",
                                "criterion": "cytogenetic abnormalities",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "t(15;17)(q24;q21) PML/RARA, t(8;21)(q22;q22) RUNX1/RUNX1T1, inv(16)(p13q22)/t(16;16)(p13;q22) CBFB-MYH11",
                "criterions": [
                    {
                        "exact_snippets": "t(15;17)(q24;q21) PML/RARA",
                        "criterion": "t(15;17)(q24;q21) PML/RARA translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "t(8;21)(q22;q22) RUNX1/RUNX1T1",
                        "criterion": "t(8;21)(q22;q22) RUNX1/RUNX1T1 translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "inv(16)(p13q22)/t(16;16)(p13;q22) CBFB-MYH11",
                        "criterion": "inv(16)(p13q22) or t(16;16)(p13;q22) CBFB-MYH11 rearrangement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "t(15;17)(q24;q21) PML/RARA",
                        "criterion": "t(15;17)(q24;q21) PML/RARA translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "t(8;21)(q22;q22) RUNX1/RUNX1T1",
                        "criterion": "t(8;21)(q22;q22) RUNX1/RUNX1T1 translocation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "inv(16)(p13q22)/t(16;16)(p13;q22) CBFB-MYH11",
                        "criterion": "inv(16)(p13q22) or t(16;16)(p13;q22) CBFB-MYH11 rearrangement",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled active seizure disorder",
                        "criterion": "seizure disorder",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled active seizure disorder",
                        "criterion": "seizure disorder",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
                        "criterion": "psychiatric illness or social situations",
                        "requirement": {
                            "requirement_type": "PI judgment of impact on compliance",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "Uncontrolled undercurrent illness including, but not limited to, symptomatic congestive heart failure",
                                "criterion": "congestive heart failure",
                                "requirement": {
                                    "requirement_type": "symptomatic",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "angina pectoris",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "uncontrolled active seizure disorder",
                                "criterion": "seizure disorder",
                                "requirement": {
                                    "requirement_type": "control status",
                                    "expected_value": "uncontrolled"
                                }
                            },
                            {
                                "exact_snippets": "uncontrolled active seizure disorder",
                                "criterion": "seizure disorder",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": "active"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "psychiatric illness/social situations that per site Principal Investigator's judgment would limit compliance with study requirements",
                        "criterion": "psychiatric illness or social situations",
                        "requirement": {
                            "requirement_type": "PI judgment of impact on compliance",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A history or presence of clinically relevant CNS pathology (e.g., as epilepsy, paresis, aphasia, stroke, severe brain injuries, dementia, cerebellar disease, psychosis)",
                "criterions": [
                    {
                        "exact_snippets": "A history or presence of clinically relevant CNS pathology",
                        "criterion": "CNS pathology",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A history or presence of clinically relevant CNS pathology",
                        "criterion": "CNS pathology",
                        "requirement": {
                            "requirement_type": "clinical relevance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "epilepsy",
                        "criterion": "epilepsy",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "paresis",
                        "criterion": "paresis",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "aphasia",
                        "criterion": "aphasia",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "severe brain injuries",
                        "criterion": "severe brain injuries",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "dementia",
                        "criterion": "dementia",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cerebellar disease",
                        "criterion": "cerebellar disease",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "psychosis",
                        "criterion": "psychosis",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A history or presence of clinically relevant CNS pathology",
                                "criterion": "CNS pathology",
                                "requirement": {
                                    "requirement_type": "history or presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A history or presence of clinically relevant CNS pathology",
                                "criterion": "CNS pathology",
                                "requirement": {
                                    "requirement_type": "clinical relevance",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "epilepsy",
                        "criterion": "epilepsy",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "paresis",
                        "criterion": "paresis",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "aphasia",
                        "criterion": "aphasia",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "severe brain injuries",
                        "criterion": "severe brain injuries",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "dementia",
                        "criterion": "dementia",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "cerebellar disease",
                        "criterion": "cerebellar disease",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "psychosis",
                        "criterion": "psychosis",
                        "requirement": {
                            "requirement_type": "history or presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Subjects who have undergone allo-HSCT are eligible if they are ≥ 4 weeks post stem cell infusion, have no evidence of GVHD > Grade 2, and are at least ≥ 1 week off all immunosuppressive therapy",
                "criterions": [
                    {
                        "exact_snippets": "undergone allo-HSCT",
                        "criterion": "allogeneic hematopoietic stem cell transplantation (allo-HSCT)",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "≥ 4 weeks post stem cell infusion",
                        "criterion": "time since stem cell infusion",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no evidence of GVHD > Grade 2",
                        "criterion": "graft-versus-host disease (GVHD)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least ≥ 1 week off all immunosuppressive therapy",
                        "criterion": "time off immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "time off therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "undergone allo-HSCT",
                        "criterion": "allogeneic hematopoietic stem cell transplantation (allo-HSCT)",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "\u001e 4 weeks post stem cell infusion",
                        "criterion": "time since stem cell infusion",
                        "requirement": {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "no evidence of GVHD > Grade 2",
                        "criterion": "graft-versus-host disease (GVHD)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "at least \u001e 1 week off all immunosuppressive therapy",
                        "criterion": "time off immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "time off therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with a history of CNS leukemia must be clinically stable with a flow cytometric clear CSF in the 2 weeks prior to day 1 of blinatumomab administration. Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration. Subject can receive subsequent prophylactic intrathecal chemotherapy.",
                "criterions": [
                    {
                        "exact_snippets": "Subjects with a history of CNS leukemia must be clinically stable",
                        "criterion": "clinical stability in subjects with history of CNS leukemia",
                        "requirement": {
                            "requirement_type": "clinical stability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "flow cytometric clear CSF in the 2 weeks prior to day 1 of blinatumomab administration",
                        "criterion": "CSF flow cytometry in subjects with history of CNS leukemia",
                        "requirement": {
                            "requirement_type": "flow cytometric clearance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "flow cytometric clear CSF in the 2 weeks prior to day 1 of blinatumomab administration",
                        "criterion": "CSF flow cytometry in subjects with history of CNS leukemia",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days before day 1 of blinatumomab administration"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration",
                        "criterion": "intrathecal chemotherapy in Cohort A subjects with history of CNS leukemia",
                        "requirement": {
                            "requirement_type": "dose received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "dose"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration",
                        "criterion": "intrathecal chemotherapy in Cohort A subjects with history of CNS leukemia",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days before day 1 of blinatumomab administration"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Subjects with a history of CNS leukemia must be clinically stable",
                                "criterion": "clinical stability in subjects with history of CNS leukemia",
                                "requirement": {
                                    "requirement_type": "clinical stability",
                                    "expected_value": true
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "flow cytometric clear CSF in the 2 weeks prior to day 1 of blinatumomab administration",
                                        "criterion": "CSF flow cytometry in subjects with history of CNS leukemia",
                                        "requirement": {
                                            "requirement_type": "flow cytometric clearance",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "flow cytometric clear CSF in the 2 weeks prior to day 1 of blinatumomab administration",
                                        "criterion": "CSF flow cytometry in subjects with history of CNS leukemia",
                                        "requirement": {
                                            "requirement_type": "timing",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 14,
                                                "unit": "days before day 1 of blinatumomab administration"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "condition": {
                            "exact_snippets": "Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration",
                            "criterion": "intrathecal chemotherapy in Cohort A subjects with history of CNS leukemia",
                            "requirement": {
                                "requirement_type": "dose received",
                                "expected_value": {
                                    "operator": ">=",
                                    "value": 0,
                                    "unit": "dose"
                                }
                            }
                        },
                        "then_criteria": {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration",
                                    "criterion": "intrathecal chemotherapy in Cohort A subjects with history of CNS leukemia",
                                    "requirement": {
                                        "requirement_type": "dose received",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 1,
                                            "unit": "dose"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Subjects with history of CNS leukemia in Cohort A should have received one dose of intrathecal chemotherapy in the 4 weeks prior to day 1 of blinatumomab administration",
                                    "criterion": "intrathecal chemotherapy in Cohort A subjects with history of CNS leukemia",
                                    "requirement": {
                                        "requirement_type": "timing",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 28,
                                            "unit": "days before day 1 of blinatumomab administration"
                                        }
                                    }
                                }
                            ]
                        },
                        "else_criteria": null
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects must have histologically or cytologically confirmed R/R CD19-positive MPAL based on the WHO criteria, OR CD19-positive MPAL in CR/CRh/CRi/CRp after at least one chemotherapy block of standard ALL or AML therapy with detectable MRD ≥ 0.1%. Primary refractory MPAL is defined by absence of CR/CRh/CRi/CRp after at least one cycle of standard AML/ALL induction therapy. A patient has relapsed MPAL if they achieved a CR/CRh/CRi/CRp after induction therapy (CR1) and has then relapsed during, or after continuation of therapy.",
                "criterions": [
                    {
                        "exact_snippets": "histologically or cytologically confirmed R/R CD19-positive MPAL based on the WHO criteria",
                        "criterion": "MPAL diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "histologically or cytologically confirmed R/R CD19-positive MPAL based on the WHO criteria",
                        "criterion": "MPAL diagnosis",
                        "requirement": {
                            "requirement_type": "disease status",
                            "expected_value": "relapsed or refractory (R/R)"
                        }
                    },
                    {
                        "exact_snippets": "histologically or cytologically confirmed R/R CD19-positive MPAL based on the WHO criteria",
                        "criterion": "MPAL diagnosis",
                        "requirement": {
                            "requirement_type": "CD19 expression",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "histologically or cytologically confirmed R/R CD19-positive MPAL based on the WHO criteria",
                        "criterion": "MPAL diagnosis",
                        "requirement": {
                            "requirement_type": "diagnostic criteria",
                            "expected_value": "WHO criteria"
                        }
                    },
                    {
                        "exact_snippets": "CD19-positive MPAL in CR/CRh/CRi/CRp after at least one chemotherapy block of standard ALL or AML therapy with detectable MRD ≥ 0.1%",
                        "criterion": "MPAL disease status after therapy",
                        "requirement": {
                            "requirement_type": "CD19 expression",
                            "expected_value": "positive"
                        }
                    },
                    {
                        "exact_snippets": "CD19-positive MPAL in CR/CRh/CRi/CRp after at least one chemotherapy block of standard ALL or AML therapy with detectable MRD ≥ 0.1%",
                        "criterion": "MPAL disease status after therapy",
                        "requirement": {
                            "requirement_type": "remission status",
                            "expected_value": [
                                "CR",
                                "CRh",
                                "CRi",
                                "CRp"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "CD19-positive MPAL in CR/CRh/CRi/CRp after at least one chemotherapy block of standard ALL or AML therapy with detectable MRD ≥ 0.1%",
                        "criterion": "MPAL disease status after therapy",
                        "requirement": {
                            "requirement_type": "prior therapy",
                            "expected_value": "at least one chemotherapy block of standard ALL or AML therapy"
                        }
                    },
                    {
                        "exact_snippets": "CD19-positive MPAL in CR/CRh/CRi/CRp after at least one chemotherapy block of standard ALL or AML therapy with detectable MRD ≥ 0.1%",
                        "criterion": "MPAL disease status after therapy",
                        "requirement": {
                            "requirement_type": "MRD level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.1,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Subjects receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy not including corticosteroids or hydroxyurea",
                "criterions": [
                    {
                        "exact_snippets": "Subjects receiving any other investigational agents",
                        "criterion": "receipt of investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "concurrent chemotherapy",
                        "criterion": "concurrent chemotherapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "concurrent ... radiation therapy",
                        "criterion": "concurrent radiation therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "concurrent ... immunotherapy not including corticosteroids or hydroxyurea",
                        "criterion": "concurrent immunotherapy (excluding corticosteroids or hydroxyurea)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Subjects receiving any other investigational agents",
                        "criterion": "receipt of investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "concurrent chemotherapy",
                        "criterion": "concurrent chemotherapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "concurrent ... radiation therapy",
                        "criterion": "concurrent radiation therapy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "concurrent ... immunotherapy not including corticosteroids or hydroxyurea",
                        "criterion": "concurrent immunotherapy (excluding corticosteroids or hydroxyurea)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}